Karyopharm Therapeutics (KPTI) Liabilities and Shareholders Equity (2012 - 2025)

Karyopharm Therapeutics has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $108.4 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 34.06% year-over-year to $108.4 million; the trailing twelve-month figure through Dec 2025 stood at $437.2 million (down 43.39% YoY), and the FY2025 full-year result was $108.4 million, down 34.06% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $108.4 million, up from $96.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $358.2 million in Q4 2022, with the low at $96.2 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $230.2 million across 5 years, with a median of $247.3 million in 2021.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 17.32% — and 2025, when it tumbled 50.99%.
• Karyopharm Therapeutics' Liabilities and Shareholders Equity stood at $305.3 million in 2021, then grew by 17.32% to $358.2 million in 2022, then slumped by 32.87% to $240.4 million in 2023, then sank by 31.62% to $164.4 million in 2024, then plunged by 34.06% to $108.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $108.4 million (Q4 2025), $96.2 million (Q3 2025), and $104.9 million (Q2 2025), per Business Quant data.